Finance

Pharmaceutical company reports third quarter revenue increase of 58%

Published in Cancer Weekly, December 7th, 2004

Ligand Pharmaceuticals reported record net product sales for the third quarter ended Sept. 30, 2004, of $44.7 million, compared to $28.1 million the third quarter of 2003, an increase of 59% driven by strong Avinza (morphine sulphate extended-release capsules) net sales of $28.3 million and Targretin capsules and gel sales of $6.2 million.

Ligand's total revenues for the third quarter of 2004 were $49.5 million, compared to $31.3 million for the same period in 2003, an increase of 58%. Net loss for the third quarter of 2004 was $6.8 million ($.09 per share), compared to a net loss of $11.1 million ($.16 per share) for the same period in 2003, an improvement of 39% (44%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry